Company
WuXi Biologics
Headquarters: Wuxi, China
Employees: 9,864
CEO: Dr. Zhisheng Chen
Market Cap
HK$271.11 Billion
HKD as of Jan. 1, 2023
US$34.54 Billion
WuXi Biologics Categories
China
languages
Healthcare
languages
Biotechnology
China Healthcare
China Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
Novo Nordisk
|
$304.61 B |
CSL Limited
|
$93.24 B |
Regeneron Pharmaceuticals, Inc.
|
$79.53 B |
| Marinomed Biotech AG | $76.72 B |
|
Vertex Pharmaceuticals Incorporated
|
$74.13 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$495.37 B |
|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
|
Novo Nordisk
|
$304.61 B |
|
Pfizer
|
$287.63 B |
Detailed Description
WuXi Biologics (Cayman) Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. It has strategic partnerships with Almirall, S.A.; Vir Biotechnology, Inc.; Aravive, Inc.; Tubulis GmbH; Arcus Biosciences, Inc.; AC Immune SA; and AB2 Bio Ltd. The company was incorporated in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.
Stocks & Indices
WuXi Biologics has the following listings and related stock indices.
Stock: HKEX: 2269
Stock: FSX: 1FW1
Stock: OTC: WXIBF